A Phase 3 interventional study of Dimebon and Dimebon in Alzheimer's Disease, sponsored by Medivation, Inc.. Completed at 101 sites in 10 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-09-27.
Sponsored by Medivation, Inc. · Phase 3, Interventional, and Treatment
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
3,675 studies on the registry are indexed under Alzheimer Disease; 869 are open to participants now.
This study's enrollment of 1,003 is above the median of 70 across 2,805 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Medivation, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dimebon, 5 mg orally three times daily
Drug: Dimebon
Dimebon, 20 mg orally three times daily
Drug: Dimebon
Placebo orally three times daily
Drug: Placebo comparator
5 mg orally three times daily
20 mg orally three times daily
Placebo orally three times daily
Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
Time frame: Week 52
Alzheimer's Disease Assessment Scale - Cognitive Subscale
Time frame: Week 52
Clinician's Interview Based Impression of Change, plus caregiver input (CIBIC-plus)
Time frame: Week 52
Neuropsychiatric Inventory (NPI)
Time frame: Week 52
Resource Utilization in Dementia Lite (RUD lite)
Time frame: Week 52
Euro Quality of Life 5 (EQ-5D)
Time frame: Week 52
Showing the first 100 of 101 sites across 10 countries.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medivation, Inc.